Aquestive Therapeutics Inc (AQST)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Aquestive Therapeutics Inc Stock (AQST) Company Profile

Aquestive Therapeutics Inc

Healthcare (1166)

908-941-1900

30 TECHNOLOGY DRIVE, WARREN, NJ

Nächster Verdiensttermin

Neueste SEC-Einreichungen

AQST's Discussions on Twitter

Vergleichen Sie AQST mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AQST Aquestive Therapeutics Inc	3.68	338.71M	58.36M	-25.72M	-24.91M	-0.3641
RGC Regencell Bioscience Holdings Ltd	10.36	303.95B	0	-5.87M	-767.30K	-0.45
ZTS Zoetis Inc	159.08	74.39B	9.29B	2.52B	2.28B	5.57
HLN Haleon Plc Adr	10.26	48.97B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	15.42	47.39B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	17.05	20.17B	16.54B	-1.64B	749.00M	-1.45

Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-06-02	Fortgesetzt	Oppenheimer	Outperform
2024-12-17	Eingeleitet	Cantor Fitzgerald	Overweight
2024-05-10	Eingeleitet	Leerink Partners	Outperform
2024-04-11	Eingeleitet	Piper Sandler	Overweight
2024-03-28	Eingeleitet	Raymond James	Outperform
2021-04-07	Fortgesetzt	RBC Capital Mkts	Outperform
2019-04-22	Eingeleitet	H.C. Wainwright	Buy
2019-01-03	Eingeleitet	Lake Street	Buy
2018-08-20	Eingeleitet	JMP Securities	Mkt Outperform
2018-08-20	Eingeleitet	RBC Capital Mkts	Outperform

Alle ansehen

Aquestive Therapeutics Inc Aktie (AQST) Neueste Nachrichten

Finanzdaten der Aquestive Therapeutics Inc-Aktie (AQST)

Aquestive Therapeutics Inc (AQST)

Aquestive Therapeutics Inc Stock (AQST) Company Profile

Vergleichen Sie AQST mit anderen Aktien

Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades

Aquestive Therapeutics Inc Aktie (AQST) Neueste Nachrichten

Aquestive gains as allergy therapy undergoes FDA review - MSN

BRIEF—FDA accepts NDA for Aquestive’s Anaphylm - The Pharma Letter

AQST: HC Wainwright & Co. Reiterates Buy Rating for Aquestive Therapeutics | AQST Stock News - GuruFocus

Aquestive stock gains on FDA review for allergy drug (AQST) - Seeking Alpha

Aquestive Gets FDA Acceptance of New Drug Application for Severe Allergic Reaction Treatment - MarketScreener

AQST Stock: FDA Accepts NDA for Anaphylm to Treat Severe Allergic Reactions | AQST Stock News - GuruFocus

FDA accepts Aquestive’s NDA for oral epinephrine film with 2026 target date - Investing.com Canada

Aquestive Therapeutics Announces FDA Acceptance of New Drug - GlobeNewswire

Revolutionary Needle-Free Epinephrine Treatment Advances: FDA Sets 2026 Decision Date for Oral Anaphylaxis Drug - Stock Titan

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Rating of “Buy” by Analysts - Defense World

Research Analysts Offer Predictions for AQST FY2026 Earnings - Defense World

Aquestive Therapeutics Holds Annual Stockholders Meeting - TipRanks

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by Millennium Management LLC - Defense World

Two Sigma Advisers LP Takes $57,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

Two Sigma Investments LP Buys 42,160 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share (NASDAQ:AQST) - Seeking Alpha

Jane Street Group LLC Sells 44,603 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

Wellington Management Group LLP Sells 5,579 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

BNP Paribas Financial Markets Sells 7,286 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stake Lifted by ProShare Advisors LLC - Defense World

Oppenheimer Begins Coverage on Aquestive Therapeutics (NASDAQ:AQST) - Defense World

Aquestive Therapeutics (NASDAQ:AQST) Earns Outperform Rating from Analysts at Oppenheimer - Defense World

Aquestive Therapeutics (NASDAQ:AQST) Coverage Initiated at Oppenheimer - Defense World

Oppenheimer Initiates Coverage on Aquestive Therapeutics (NASDAQ:AQST) - Defense World

Aquestive Therapeutics (NASDAQ:AQST) Now Covered by Analysts at Oppenheimer - Defense World

Aquestive Therapeutics (AQST) Receives Positive Coverage and Sets Future Milestones | AQST Stock News - GuruFocus

Deutsche Bank AG Grows Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

Aquestive Therapeutics (NASDAQ:AQST) Now Covered by Oppenheimer - Defense World

Aquestive Therapeutics Prepares for FDA Approvals and Launches - TipRanks

AQST: Oppenheimer Lowers Price Target for Aquestive Therapeutics - GuruFocus

AQST: Oppenheimer Lowers Price Target for Aquestive Therapeutics | AQST Stock News - GuruFocus

Oppenheimer lowers Aquestive Therapeutics stock price target to $7 By Investing.com - Investing.com Canada

Oppenheimer Adjusts Price Target for Aquestive Therapeutics (AQST) | AQST Stock News - GuruFocus

Bank of America Corp DE Boosts Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

D. E. Shaw & Co. Inc. Has $450,000 Stock Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

Those who invested in Aquestive Therapeutics (NASDAQ:AQST) three years ago are up 128% - Yahoo

Northern Trust Corp Has $2.14 Million Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World

Aquestive Therapeutics, Inc. (AQST): Analysts See 245% Upside Potential - Insider Monkey

13 Best Multibagger Stocks to Invest in Now - Insider Monkey

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of “Buy” by Analysts - Defense World

Q2 EPS Forecast for Aquestive Therapeutics Cut by Analyst - Defense World

AQST FY2025 EPS Estimate Lowered by Cantor Fitzgerald - Defense World

Q2 Earnings Forecast for AQST Issued By Leerink Partnrs - Defense World

HC Wainwright Reaffirms Buy Rating for Aquestive Therapeutics (NASDAQ:AQST) - Defense World

Aquestive Therapeutics targets $44M–$50M revenue in 2025 as Anaphylm launch preparations accelerate - MSN

Analysts Have Lowered Expectations For Aquestive Therapeutics, Inc. (NASDAQ:AQST) After Its Latest Results - simplywall.st

Aquestive Therapeutics’ Earnings Call: Mixed Outlook - TipRanks

AQST: Aquestive Therapeutics Receives Continued "Buy" Rating from HC Wainwright | AQST Stock News - GuruFocus

Lake Street Reaffirms Their Buy Rating on Aquestive Therapeutics (AQST) - The Globe and Mail

AQST: Aquestive Therapeutics Receives Continued "Buy" Rating fro - GuruFocus

Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS), Aquestive Therapeutics (AQST) and Olema Pharmaceuticals (OLMA) - The Globe and Mail

Finanzdaten der Aquestive Therapeutics Inc-Aktie (AQST)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie AQST